Brand name: CADITHRO (Rulide, Roxithromycin)

CADITHRO (Rulide, Roxithromycin)
Systematic (IUPAC) name

Identifiers

Therapeutic considerations

CADITHRO (Rulide, Roxithromycin) is a semi-synthetic macrolide antibiotic. It is used to treat respiratory tract, urinary and soft tissue infections. CADITHRO (Rulide, Roxithromycin) is derived from erythromycin, containing the same 14-membered lactone ring. However, an N-oxime side chain is attached to the lactone ring.

CADITHRO (Rulide, Roxithromycin) is available under several brandnames, for example Surlid, Rulide, Biaxsig, Roxar and Roximycin.
Contents

* 1 History * 2 Available forms * * 3 Mechanism of action * 4 Pharmacokinetics * 5 Metabolism * 6 Side effects * 7 Drug interactions History

German pharmaceutical company Hoechst Uclaf brought out CADITHRO (Rulide, Roxithromycin) in 1987.

Available forms *

CADITHRO (Rulide, Roxithromycin) is commonly available as tablets or oral suspension.

Mechanism of action CADITHRO (Rulide, Roxithromycin)

CADITHRO (Rulide, Roxithromycin) prevents bacteria from growing, by interfering with their protein synthesis. CADITHRO (Rulide, Roxithromycin) binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. CADITHRO (Rulide, Roxithromycin) has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila.

Pharmacokinetics

When taken before a meal, CADITHRO (Rulide, Roxithromycin) is very rapidly absorbed, and diffused into most tissues and phagocytes. Due to the high concentration in phagocytes, CADITHRO (Rulide, Roxithromycin) is actively transported to the site of infection. During active phagocytosis, large concentrations of CADITHRO (Rulide, Roxithromycin) are released.

Metabolism

Only a small portion of CADITHRO (Rulide, Roxithromycin) is metabolised. Most of CADITHRO (Rulide, Roxithromycin) is secreted unchanged into the bile and some in expired air. Under 10% is excret